Small Molecules, Big Impact: The Future Of Oral Solid Dose Development And Innovation

In this insightful interview, Tom Sellig, CEO of Adare, discusses the continued importance of small molecule products in the pharmaceutical industry. He highlights the focus on oral solid dose (OSD) development, commercial packaging, and analytical services, particularly for small molecule products. Despite the increasing interest in biologics, small molecules remain a cornerstone of global pharmaceutical efforts, with around 80% of medications being oral solid doses. Sellig emphasizes that small molecules are not only relevant but are evolving with trends such as the transition of GLP-1 treatments from injectables to oral formulations, which opens up new opportunities in areas like pediatric and geriatric medicine. CNS (central nervous system), oncology, and obesity/weight management are significant therapeutic areas where small molecules continue to make a large impact. He also notes the importance of both non-pain and pain-related products, which remain a major segment in the global market.

A major area of innovation for Adare is 3D printing, which they have implemented in three of their facilities. This technology offers flexibility in development, including the ability to combine multiple active pharmaceutical ingredients (APIs) into a single tablet and embed QR codes for individual tablet tracking. Sellig explains how 3D printing can accelerate development timelines and enhance the responsiveness of the pharmaceutical development process. Overall, this conversation offers a detailed perspective on how small molecules and innovative technologies are shaping the future of drug development.